3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Neoplasm Metastasis
4
Colorectal Neoplasms
2
Pancreatic Neoplasms
1
Neoplasms
1
HER2-Positive Primary Breast Cancer
1
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Adenocarcinoma
1
Interventions
Afatinib
2
zenocutuzumab
1
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olaparib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
entrectinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
adagrasib
1
X-Rays
1
Trastuzumab
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Pancreatic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT04482309
2026-04-09
DPT02
AstraZeneca
Phase 2
Active not recruiting
477 enrolled
1 FDA